iCo Therapeutics iCo-007 Second Cohort Results to be Presented at Cleveland Clinic Ocular Conference
March 17, 2009
VANCOUVER, Canada— iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that preliminary results for the first two cohorts from the ongoing clinical trial for iCo’s Diabetic Macular Edema (DME) candidate, iCo-007, will be featured in a presentation at an important ocular conference.
The presentation will be given by Philip J. Rosenfeld, MD, PhD, Professor of Ophthalmology at the Bascom Palmer Eye Institute University of Miami Miller School of Medicine. Dr. Rosenfeld is an investigator participating in the Phase I clinical trial in DME patients. The primary endpoint of the open label, dose escalating trial is safety, with visual acuity and measures of retinal thickness serving as secondary endpoints.
The conference, “Innovations in Ophthalmology”, will be held from March 16th-19th, 2009 in Key Largo, Florida. The Cleveland Clinic conference will feature prominent ophthalmology experts discussing the prevention, diagnostics, and treatment of eye disease. Dr. Rosenfeld’s presentation is titled, “Anti-VEGF Therapy for Macular Edema”, and will be held on Wednesday March 18th during the “Current Management of Diabetic Retinopathy and Vein Occlusion” session.
About iCo-007
iCo-007 is expected to decrease swelling in the retina and related visual impairment by decreasing the signaling of multiple growth factors, including VEGF, IGF, bFGF, EPO and HGF that signal through the c-Raf kinase / MAP kinase pathway. iCo-007 may also be a potential treatment for certain oncology indications, as c-Raf kinase is the predominant Raf isoform responsible for regulating cellular growth in ovarian cancer. iCo-007 is an antisense drug discovered by Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and licensed to iCo Therapeutics for the treatment of various eye diseases.
